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Abstract 
Introduction: Diabetes mellitus (DM) is a primary disease of the carbohydrate metabolism that 
is characterised by absolute or relative insulin deficiency, or insulin resistance. Although life 
expectancy is low for diabetic patients, the prognosis has been improved in recent decades. 
Metformin is an oral antidiabetic that reduces insulin resistance and plasma glucose levels by 
decreasing glucose production in the liver. It can be used as a standalone treatment or in 
combination with other antidiabetic medications or insulin. Urotensin 2 (U-II), which is one of 
the most effective known vasoconstrictor peptides, was observed to act as a vasoconstrictor in 
diseases such as hypertension and heart failure, and to induce vasodilation in healthy volunteers. 
Some studies have proposed that the activation of the U-II system could lead to metabolic 
syndrome. Certain studies have determined a link between DM and U-II. However, there exist no 
  
studies on the effects of U-II in recently diagnosed type 2 DM patients after metformin 
treatment. 
This study aims to investigate the plasma and saliva levels of U-II at diagnosis and after a three-
month metformin treatment in recently diagnosed type 2 DM patients, and to compare these 
levels to those of healthy volunteers. 
Material and methods: Our study compared 30 recently diagnosed type 2 DM patients to their 
states after three-month metformin treatment and 30 healthy volunteers.   
Results: When compared with the control group, there was no significant increase in the plasma 
and saliva U-II levels of recently diagnosed type 2 DM patients. We determined a statistically 
significant increase in the plasma and saliva ureotensin-2 levels of recently diagnosed type 2 DM 
patients after a three-month metformin treatment (p < 0.05). 
Conclusions: It was concluded that the patients with type 2 DM have a multifactorial 
aetiopathogenesis and an increase in U-II levels after metformin treatment. Metformin has no 
known effect on the U-II metabolism; therefore, the findings need confirmation through more 
clinical and experimental studies with more participants. 
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Introduction 
Type 2 diabetes mellitus (DM) is a primary disorder of the carbohydrate mechanism, which has 
chronic progression, a multifactorial aetiopathogenesis, is characterised by absolute or relative 
insulin deficiency or insulin resistance, presents with high plasma glucose levels as the primary 
symptom, demonstrates significant changes in lipid and protein metabolisms, and displays a 
heterogeneous clinical picture [1, 2]. 
Besides its acute complications, DM progresses with chronic complications such as retinopathy, 
which causes vision loss in the long term; nephropathy and vascular diseases, which cause renal 
failure; neuropathy, which ultimately results in the amputation of the foot; and additionally, with 
autonomous neuropathy, which can lead to cardiovascular, genitourinary, gastrointestinal system 
disorders; and sexual function disorders; and poses a high morbidity and early mortality risk [3, 
4]. 
The prevalence of DM has been gradually increasing. The International Diabetes Federation 
(IDF) predicts that the number of diabetic patients, which was 425 million in 2017, will reach 
  
629 million by 2045. According to International Diabetes Federation (IDF) data, it is estimated 
that 4 million people between the ages of 20 and 79 years died because of diabetes in 2017 [5]. 
Urotensin 2 (U-II) is one of the strongest known vasoconstrictor peptides, and it is even stronger 
than endothelin-1, which is renowned for its vasoconstrictor properties. U-II is a peptide that is 
made up of 11 amino acids. The U-II molecule was first detected in the spinal cord of fish. It 
contains peptide sequences that resemble somatostatin. The U-II peptide arises from the prepro-
U-II molecule, which is a large precursor molecule. Plasma urotensin levels were found to be 
elevated in renal failure, diabetes, hypertension, congestive heart failure, and portal hypertension. 
While U-II acts as a vasoconstrictor in diseases such as hypertension and heart failure, it was 
seen to induce vasodilation in healthy volunteers [6–9]. Urine and plasma U-II levels of type 2 
diabetic patients were found to be higher in those with disrupted renal function than in those with 
normal renal function [10]. Tubular epithelial cells obtained from the nephrectomy of patients 
with diabetic nephropathy showed an overexpression of U-II and the urotensin receptor [11]. U-
II was shown to activate “nicotinamide adenine dinucleotide phosphate oxidase” in vascular 
muscle cells. Oxidative stress, which is elevated by this pathway, was proposed to contribute 
significantly to the development of diabetic retinopathy [12–14]. Recent studies have 
demonstrated that U-II can be used as a biomarker in type 2 DM patients with diabetic 
nephropathy and atherosclerosis and rheumatic valvular disease [15]. In the present study, we 
investigate the relationship of plasma and saliva levels of U-II with type 2 DM. 
 
Material and methods 
Participants 
Prior to the study, ethical approval was obtained from Firat University Non-Invasive Research 
Ethics Committee Directorate (Date: 30.03.2017, Approval number: 06/45). This study included: 
30 patients who presented to the Internal Diseases polyclinic and received a diagnosis of type 2 
DM, and started metformin treatment following the diagnosis; and 30 healthy volunteers who 
presented to our polyclinic for a general check-up and were found to have no diseases. 
Individuals who were diagnosed with diabetes and who previously had had hypertension, any 
known cardiovascular diseases, a history of malignancy, an infection, acute/chronic kidney 
failure, acute/chronic liver disease, a history of steroid use, a history of immunosuppressive 
medication use, were pregnant, or experienced communication difficulties related to 
  
sociocultural competence were excluded from the study. The demographic data (age and sex) of 
the entire study group were recorded from patient files. Diagnosis of diabetes was based on the 
following criteria: fasting plasma glucose ≥ 126 mg/dL, two-hour glucose level ≥ 200 mg/dL in 
75-gram glucose tolerance test, and HbA1c ≥ 6.5%. 
 
Samples 
Besides fasting plasma glucose, the following metabolic parameters were determined for both 
the study group and the control group: serum lipid levels (total cholesterol, LDL, triglyceride), 
liver and kidney function tests (ALT, AST, urea, creatinine), and haemogram values. For the 
study group, postprandial plasma glucose and HbA1c levels were also investigated in order to 
better evaluate the glycaemic states. Both the healthy control group and the patients provided 4 
ml blood samples from the left antecubital region and 4 ml saliva at the initial presentation, and 
these were collected in tubes with a protease inhibitor (aprotinin). Blood samples were placed 
into EDTA tubes, lightly shaken, and promptly transported to the biochemistry laboratory on ice 
blocks. These samples were centrifuged at 3500 rpm for 10 min. They were then transferred to 
Eppendorf tubes and stored at –20°C until retrieved for the assay. Saliva samples were also 
collected into aprotinin tubes, centrifuged by the same method, and stored at –20°C until 
retrieved for the assay. U-II (U-II/UCN2) levels (Human U-II/UCN2; catalogue no: 201-12-5285 
Sunred Biological Technology Co., Ltd, Shanghai, CHINA) of the serum and saliva samples 
were determined with the Elisa method in accordance with the assay procedures described in the 
kit catalogue. The human UCN2 ELISA kit had a measurement range of 0.1-15 pmol/L, an intra-
assay CV value < 10%, an inter-assay CV value < 12%, and a sensitivity of 0.055 pmol/L. Plate 
washing was performed using the automatic microplate washer Bio-Tek ELX50 (BioTek 
Instruments, USA) and absorbance readings were taken using the ChroMate, Microplate Reader 
P4300 (Awareness Technology Instruments, USA) device. Test results were presented in 
pmol/L. The measurement of U-II in saliva samples by the U-II kit was assessed according to the 
procedure published by Aydin, and the kit was determined to measure U-II in saliva samples as 
well [16]. 
 
Immunohistochemistry 
  
For U-II immunoreactivity, the submandibular and parotid salivary glands were used. Five- to 
six-millimetre sections obtained from paraffin blocks were mounted onto polylysine slides. After 
being deparaffinised, the tissues were passed through alcohol series and boiled 7 + 5 min. in 
citrate buffer solution at pH 6 in a microwave oven (750 W) for antigen retrieval. After boiling, 
they were cooled at room temperature for 20 min., washed with PBS (Phosphate Buffered Saline, 
P4417, Sigma-Aldrich, USA) for 3 × 5 min., and incubated with hydrogen peroxide blocking 
solution for 5 min. in order to prevent endogenous peroxidase activity (Hydrogen Peroxide 
Block, TA-125-HP, Lab Vision Corporation, USA). After washing the tissues with PBS for 3 × 5 
min., Ultra V Block solution (TA–125-UB, Lab Vision Corporation, USA) was applied onto the 
tissues for 5 min. to prevent non-specific background staining, and they were incubated with the 
primary antibody (urotensin II antibody, sc-52300, Santa Cruz Biotechnology, California, USA), 
which was diluted at 1:200 for 60 min. at room temperature in a humid environment. After the 
primary antibody application, the tissues were washed with PBS for 3 × 5 min. and incubated 
with the secondary antibody (biotinylated Goat Anti-Polyvalent [anti-mouse / rabbit IgG], TP-
125-BN, Lab Vision Corporation, USA) for 30 min. at room temperature in a humid 
environment. After the secondary antibody application, the tissues were washed with PBS for 3 × 
5 min. and incubated with streptavidin peroxidase (TS-125-HR Lab Vision Corporation, USA) 
for 30 min. at room temperature in a humid environment and transferred into PBS. The 3-amino-
9-ethylcarbazole (AEC) substrate + AEC chromogen (AEC Substrate, TA-015 and HAS, AEC 
Chromogen, TA-002-HAC, Lab Vision Corporation, USA) solution was dropped onto the 
tissues, and they were simultaneously washed with PBS once an image signal was acquired 
under the light microscope. The tissues were counterstained with Mayer’s haematoxylin and 
covered with the appropriate mounting solution (Large Volume Vision Mount, TA-125-UG, Lab 
Vision Corporation, USA) after being passed through PBS and distilled water. The preparates 
were evaluated and photographed using a Leica DM500 microscope (Leica DFC295). 
 
Statistical analysis 
All analyses were performed using the Statistical Package for the Social Sciences (SPSS) 
software version 22.0 (SPSS Inc., Chicago, USA). The data were analysed using descriptive 
statistical methods, Student’s t-test, equivalents, and variance analysis. This study considered p < 
0.05 as the threshold for statistical significance. 
  
 
 
 
Results 
The clinical, demographic, and laboratory data of the individuals included in the study are 
summarised in Table 1.  
The diabetic patient group had a higher mean age than the healthy control group, with statistical 
significance (p < 0.001). The diabetic group manifested an even distribution of female and male 
patients, while most of the individuals that comprised the healthy control group were males. 
Fasting blood sugar levels were higher in the diabetic group, as expected (p < 0.001). No 
difference was determined between the groups in terms of liver function tests. Low-density 
lipoprotein levels (LDL) levels of the diabetic patients were significantly higher than those of the 
healthy controls at the time of diagnosis (respectively, 124.2 ± 31.9; 152.03 ± 51.3; p = 0.01); 
however, this difference between the two groups disappeared after the blood sugar levels of 
diabetics were regulated by the three-month treatment (respectively, 124.2 ± 31.9; 127.9 ± 33.6; 
p = 0.67). 
Plasma U-II levels of the healthy control group, the type 2 DM group at diagnosis, and the DM 
group after a three-month treatment were measured as 4.38 ± 2.8, 4.45 ± 2.57, and 5.9 ± 3.27 
pmol/L, respectively. A comparison of the plasma U-II levels of the DM group after a three-
month treatment with healthy controls revealed significantly higher U-II levels in the DM group 
after treatment (p = 0.015). 
Saliva U-II levels of the healthy control group, the type 2 DM group at diagnosis, and the DM 
group after 3-month treatment were measured as 4.58 ± 1.96, 4.69 ± 1.46, and 5.37 ± 1.94 
pmol/L, respectively. Although there were numerical differences between the groups with regard 
to saliva U-II levels, no statistical differences were determined.  
The light microscopic evaluation of the immunohistochemical staining performed for U-II 
immunoreactivity revealed U-II immunoreactivity in the intralobular and interlobular ducts in the 
submandibular (Fig. 1a) and parotid (Figure 1b) glands. This data indicated that U-II was 
expressed in salivary glands. 
 
Discussion 
  
The peptide molecule U-II is one of the strongest known vasoconstrictor peptides. It was seen to 
act as a vasoconstrictor in diseases such as hypertension and heart failure, while it induces 
vasodilation in healthy volunteers, and its plasma levels were found to be elevated in renal 
failure, diabetes, hypertension, congestive heart failure, and portal hypertension. Studies have 
shown that, in the heart, urotensin leads to reflex tachycardia, fibrosis, coronary vasoconstriction, 
and hypertrophy of the heart muscle [17–20]. 
The prevalence of DM, which is a chronic disease, has been increasing rapidly. Diabetes 
mellitus-related acute and chronic complications have a strong impact on life quality, morbidity, 
and mortality. However, the pathogenesis of type 2 DM causes of the associated complications 
and the involved factors have not yet been fully discovered and are still being contended. 
There are limited studies that have investigated how the U-II molecule is affected in recently 
diagnosed patients on metformin. In this study, we researched how the plasma and saliva levels 
of the U-II molecule are altered in recently diagnosed type 2 DM patients, before and after three 
months of metformin treatment. 
The present study is the first that has investigated this matter. We compared patients diagnosed 
with type 2 DM before and after three months of metformin treatment with healthy volunteers 
who had no history of any diseases or medication use. Across these groups, we determined a 
progressive numerical increase in U-II levels from the healthy control group to recently 
diagnosed type 2 DM patients, and diabetic patients after three months of treatment. However, 
this increase was only statistically significant between the plasma U-II levels of the healthy 
control group and the three-month metformin treatment group. Saliva U-II levels demonstrated a 
similar progressive increase, but these differences were not statistically significant. 
Nazer et al. [21] compared patients on metformin to those who were not, in terms of their alanine 
aminotransferase, aspartate aminotransferase, lactate dehydrogenase, and total bilirubin levels 
before and after a coronary artery bypass graft, and determined a significant decrease in those 
who used metformin. In this sense, the present data are not in accordance with our study. In our 
study, the alanine aminotransferase and aspartate aminotransferase levels of type 2 DM patients 
were not significantly different before and after three months of metformin treatment. In this 
regard, these results can be interpreted as U-II levels having no effect on liver function tests. 
In a study conducted by Anushiravani et al. [22], which included 150 patients, no statistically 
significant differences were found between the metformin group and the placebo group in terms 
  
of their alanine aminotransferase and aspartate aminotransferase enzymes. In this regard, these 
results were congruent with our findings. Therefore, it can be stated that metformin use does not 
have a hepatotoxic effect on the liver and does not have an effect on liver function tests in 
patients with normal liver function tests. 
In a study that included 60 patients diagnosed with polycystic ovary [23], Shaker et al. 
determined an increase in HDL-cholesterol levels, and a significant decrease in the total 
cholesterol/HDL-cholesterol ratio in blood tests done after three months of metformin treatment. 
Meanwhile, our study determined a statistically significant decrease in blood LDL and 
triglyceride levels of recently diagnosed type 2 DM patients after a three-month metformin 
treatment, and accordingly, metformin use was determined to have favourable effects on DM 
patients with high LDL and triglyceride levels. This positive difference might have appeared 
directly due to metformin or through the regulation of blood sugar. 
In a study by Totsune et al. [24], which included 48 patients diagnosed with type 2 DM and 10 
healthy volunteers, the patients were assigned to three groups based on their renal function tests. 
According to their classification, the first group had a creatinine clearance rate (Ccr) ≥ 70 
mL/min., the second group had a 30 ≤ Ccr < 70 mL/min., and the third group had a Ccr < 30 
mL/min. Compared to the control group, patients diagnosed with DM had significantly elevated 
U-II levels, and the highest levels were determined in the third group. As the severity of the renal 
function disorder increases, U-II levels show a progressive increase, suggesting that there is a 
cause-effect relationship between U-II and the development of renal failure. In our study, all 
groups had normal kidney function; therefore, we were not able to make such a comparison. 
In our study, no statistically significant differences were determined between the control group 
and the recently diagnosed type 2 DM patients with regard to the plasma and saliva levels of U-
II. This can be explained by the fact that the blood samples obtained from our patients 
corresponded to the early stages of the type 2 DM diagnosis and that they were obtained before 
blood sugar levels and HbA1c reached much higher levels, and, accordingly, before the 
development of microvascular and macrovascular damage. In this regard, the earlier that diabetic 
patients are diagnosed and the earlier that glycaemic control is established with early treatment, 
the more effectively the complications associated with DM will be prevented. On the other hand, 
when we investigated the plasma and saliva U-II levels of these recently diagnosed type 2 DM 
patients after three months of metformin treatment, we determined a statistically significant 
  
increase in plasma U-II levels and a numerical but insignificant increase in saliva levels. This 
difference between plasma and saliva levels could be caused by the presence of different 
enzymes and secretions in the saliva. These increases can be linked to the length of time since 
diagnosis. 
In a study conducted by Calan et al. [25] that compared 42 patients diagnosed with gestational 
DM and 42 body mass index- and age-matched controls without gestational DM, U-II levels 
were determined to be significantly higher in those with gestational DM. The authors connected 
the rise in the U-II levels of gestational DM patients to insulin resistance, high body mass index, 
and high blood glucose levels. In this regard, their results are in accordance with our results 
numerically, but not statistically. This can be explained by the exclusion of pregnant patients 
from our study, because our patients did not demonstrate pregnancy-related changes in the 
vascular structures. 
Hursitoglu et al. [26] compared 21 women diagnosed with gestational DM, 15 pregnant women 
without a DM diagnosis, and 22 age-matched, non-pregnant women. U-II levels were found to 
be significantly higher in pregnant women with and without gestational DM compared to non-
pregnant women. No statistically significant difference was found between pregnant women with 
gestational DM and those without gestational DM. In the group not diagnosed with gestational 
DM, U-II levels were found to be significantly lower after pregnancy. In terms of diabetes, the 
results of this study are similar to our results because the potential relationship between U-II and 
DM is known. In our study, there was no statistically significant difference between those with 
type 2 DM and those without DM in terms of plasma and saliva U-II levels. This can be because 
the complications associated with DM had not yet developed and glycaemic control was 
established by the early diagnosis and treatment of the patients. Therefore, early diagnosis, 
treatment, and screening are of great importance in preventing the development of disease-
related complications in DM. Although our patients were not cases of gestational DM, the results 
are similar regarding DM and suggest that there can be a cause-effect relationship between U-II 
levels and DM. 
Tabur et al. [27] compared 23 patients with concomitant DM and microalbuminuria, 23 
normoalbuminuric patients with DM, and 25 healthy controls. Compared with the 
normoalbuminuric and healthy groups, the microalbuminuric group showed significantly higher 
U-II levels. In turn, the normoalbuminuric patient group showed significantly higher U-II levels 
  
compared to the control group. These results also support the potential relationship between DM 
and U-II. The authors [27] reasoned, based on these findings, that the U-II molecule could be 
involved in the development of diabetic nephropathy. In our study, there was not a significant 
difference between the two groups. In this regard, our study is not in accordance with the study 
conducted by Tabur et al. This can be due to the absence of nephropathy symptoms in our type 2 
DM patients and the establishment of glycaemic control before the appearance of DM-related 
complications through early diagnosis and treatment. 
A study done by Gruson et al. [28] included 360 patients diagnosed with type 2 DM, 294 patients 
diagnosed with metabolic syndrome, and 66 patients without metabolic syndrome, in different 
groups. Urotensin 2 levels were found to be higher in diabetic patients with a diagnosis of 
metabolic syndrome than in those without metabolic syndrome. 
In our study, the subjects were evaluated in three categories as healthy volunteers, recently 
diagnosed type 2 DM patients, and type 2 DM patients after three months of metformin 
treatment. Blood and saliva U-II levels were not statistically different between the control group 
and the recently diagnosed type 2 DM patients. This can be because the grouping criteria we 
applied to our patient population were different than those used by Gruson et al. [28] and the 
groups were recruited from different populations. 
In a study by Siddharta et al. [29], the urotensin receptor antagonist palosuran was administered 
to type 2 DM patients, who were followed-up with dietary guidance for four weeks, and they 
determined no changes in insulin secretion, insulin sensitivity, and daily blood glucose levels 
when compared to the placebo group. In this regard, certain aspects of this study are in 
accordance with the present study. In the present study, there were no statistically significant 
differences between the U-II levels of the control group and the recently diagnosed DM group. 
This can be explained by U-II levels increasing due to the renal damage and micro- and 
macrovascular damage associated with the complications of DM rather than being a factor that 
triggers the development of this disease. The other comparison, between the healthy group and 
the recently diagnosed group after three months of metformin treatment, determined a numerical 
increase that did not reach statistical significance. Between the states of the recently diagnosed 
group and this group after three months of metformin treatment, there was a statistically 
significant increase in the plasma U-II levels and a numerical, yet statistically insignificant, 
increase in saliva U-II levels. The increase in U-II levels that appeared independently from blood 
  
glucose levels in recently diagnosed type 2 DM patients after the establishment of glycaemic 
control with metformin treatment gave us the impression that metformin influences the U-II 
metabolism through an unknown pathway or mechanism. 
 
Conclusions 
The results we obtained in this study support the notion that there exists a cause-effect 
relationship between type 2 DM and blood/saliva levels of U-II (confirming previous studies). 
Probably, this relationship would become more apparent as the time since diagnosis becomes 
longer and the DM-related complications become manifest. In this aspect, our study is the first 
on this matter, and we believe that it will serve as a reference for future studies. The uneven 
distribution of female and male patients between the healthy group and the patient group, the 
limited number of patients, and the short patient follow-up time are among the important 
limitations of our study. Experimental and clinical studies with larger patient series and long-
term observations are warranted in order to clearly determine the relationship of U-II with DM 
and the related complications. 
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Table 1. Clinical, demographic, and laboratory data of the groups included in the study 
 
Control 
(n = 30) 
DM  
0. month 
(n = 30) 
DM 
3. 
month 
(n = 30) 
 
P1 
 
P2 
 
 
P3 
Age [years] 
30.10 ± 
8.8 
54.63 ± 
10.8 
54.63 ± 
10.8 
 
˂ 
0.001 
 
˂ 
0.001 
 
> 0.05 
Gender 
[Male/Female] 
2/28 17/13 17/13 
 
– 
 
– 
 
–  
FPG [mg/dL] 
89.9 ± 
10.7 
178.3 ± 
47.10 
136.10 ± 
39.3 
 
˂ 
0.001 
 
˂ 
0.001 
 
˂ 0.001 
PPG [mg/dL]  287 ± 84.9 
217.17 ± 
77.28 
 
– 
 
– 
 
˂ 0.001 
AST [U/L] 
20.9 ± 
11.06 
23.3 ± 
13.2 
21.40 ± 
8.93 
 
0.45 
 
0.09 
 
0.22 
ALT [UL] 
22.6 ± 
14.10 
29.4 ± 
17.8 
21.90 ± 
13.09 
 
0.10 
 
0.82 
 
0.084 
Urea [mg/dL] 
25.07 ± 
7.9 
29.47 ± 
8.1 
31.37 ± 
10.73 
 
0.03 
 
0.01 
 
0.144 
Creatinine 
[mg/dL] 
0.67 ± 
0.16 
0.75 ± 
0.24 
0.75 ± 
0.23 
 
0.18 
 
0.17 
 
0.973 
Haemoglobin 
12.7 ± 
1.5 
14.2 ± 
1.78 
14.11 ± 
1.81 
 
< 0.01 
 
< 0.01 
 
> 0.05 
  
Haematocrit 
39.2 ± 
3.85 
43 ± 5.2 
42.3 ± 
4.95 
 
0.001 
 
0.008 
 
0.310 
LDL-C 
[mg/dL] 
124.2 ± 
31.90 
152.03 ± 
51.3 
127.9 ± 
33.6 
 
0.01 
 
0.67 
 
0.025 
Triglyceride 
[mg/dL] 
204.8 ± 
80.126 
255.9 ± 
150.78 
208.9 ± 
84.2 
 
0.10 
 
0.84 
 
0.04 
HBA1c (%)  7.5 ± 1.6 6.2 ± 1.2 
 
– 
 
– 
 
˂ 0.001 
UT-II  
blood 
[pmol/L] 
4.38 ± 
2.8 
4.45 ± 
2.57 
5.9 ± 
3.27 
 
0.59 
 
0.17 
 
0.015 
UT-II  
saliva 
[pmol/L] 
4.58 ± 
1.96 
4.69 ± 
1.46 
5.37 ± 
1.94 
 
0.814 
 
0.12 
 
0.060 
P1 — control with DM-0. month comparison; P2 — control with DM-3. months comparison; P3 — DM-
0. months with DM-3. months comparison; FPG — fasting plasma glucose; PPG — postprandial blood 
glucose; AST — aspartate aminotransferase; ALT — alanine aminotransferase; LDL-C — low density 
lipoprotein cholesterol; HBA1c — haemoglobin A1c; UT-II — urotensin-2 
 
 
 
Figure 1. Urotensin 2 immunoreactivity; intralobular ducts and interlobular ducts in the 
submandibular (1a) and parotid (1b) glands   
 
  
 
 
 
